These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9257330)
1. Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma. Kälkner KM; Ginman C; Nilsson S; Bergström M; Antoni G; Ahlström H; Långström B; Westlin JE Nucl Med Biol; 1997 May; 24(4):319-25. PubMed ID: 9257330 [TBL] [Abstract][Full Text] [Related]
2. PET with hydroxytryptophan as tracer in hormone-refractory prostatic adenocarcinoma: evaluation of decarboxylation in vivo. Kälkner KM; Nilsson S; Bergström M; Lindner KJ; Westerberg G; Långström B; Westlin JE In Vivo; 1997; 11(5):377-81. PubMed ID: 9427038 [TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. Orlefors H; Sundin A; Ahlström H; Bjurling P; Bergström M; Lilja A; Långström B; Oberg K; Eriksson B J Clin Oncol; 1998 Jul; 16(7):2534-41. PubMed ID: 9667275 [TBL] [Abstract][Full Text] [Related]
4. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350 [TBL] [Abstract][Full Text] [Related]
5. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702 [TBL] [Abstract][Full Text] [Related]
6. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Orlefors H; Sundin A; Lu L; Oberg K; Långström B; Eriksson B; Bergström M Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):60-5. PubMed ID: 16184369 [TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography study of human prostatic adenocarcinoma using carbon-11 putrescine. Wang GJ; Volkow ND; Wolf AP; Madajewicz S; Fowler JS; Schlyer DJ; MacGregor RR Nucl Med Biol; 1994 Jan; 21(1):77-82. PubMed ID: 9234267 [TBL] [Abstract][Full Text] [Related]
8. Uptake and utilization of [beta-11C]5-hydroxytryptophan in human brain studied by positron emission tomography. Reibring L; Agren H; Hartvig P; Tedroff J; Lundqvist H; Bjurling P; Kihlberg T; Långström B Psychiatry Res; 1992 Dec; 45(4):215-25. PubMed ID: 1292039 [TBL] [Abstract][Full Text] [Related]
9. Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Sundin A; Eriksson B; Bergström M; Bjurling P; Lindner KJ; Oberg K; Långström B Nucl Med Biol; 2000 Jan; 27(1):33-41. PubMed ID: 10755643 [TBL] [Abstract][Full Text] [Related]
10. The role of PET in localization of neuroendocrine and adrenocortical tumors. Eriksson B; Bergström M; Sundin A; Juhlin C; Orlefors H; Oberg K; Långström B Ann N Y Acad Sci; 2002 Sep; 970():159-69. PubMed ID: 12381551 [TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
12. Kinetic compartment modeling of [11C]-5-hydroxy-L-tryptophan for positron emission tomography assessment of serotonin synthesis in human brain. Hagberg GE; Torstenson R; Marteinsdottir I; Fredrikson M; Långström B; Blomqvist G J Cereb Blood Flow Metab; 2002 Nov; 22(11):1352-66. PubMed ID: 12439293 [TBL] [Abstract][Full Text] [Related]
13. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Kato T; Tsukamoto E; Kuge Y; Takei T; Shiga T; Shinohara N; Katoh C; Nakada K; Tamaki N Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1492-5. PubMed ID: 12397469 [TBL] [Abstract][Full Text] [Related]
15. Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Agren H; Reibring L; Hartvig P; Tedroff J; Bjurling P; Hörnfeldt K; Andersson Y; Lundqvist H; Långström B Acta Psychiatr Scand; 1991 Jun; 83(6):449-55. PubMed ID: 1882697 [TBL] [Abstract][Full Text] [Related]
16. 11C-5-hydroxytryptophan positron emission tomography after radiofrequency ablation of neuroendocrine tumor liver metastases. Norlén O; Nilsson A; Krause J; Stålberg P; Hellman P; Sundin A Nucl Med Biol; 2012 Aug; 39(6):883-90. PubMed ID: 22381780 [TBL] [Abstract][Full Text] [Related]
17. Whole-body MRI including diffusion-weighted MRI compared with 5-HTP PET/CT in the detection of neuroendocrine tumors. Carlbom L; Caballero-Corbalán J; Granberg D; Sörensen J; Eriksson B; Ahlström H Ups J Med Sci; 2017 Mar; 122(1):43-50. PubMed ID: 27894208 [TBL] [Abstract][Full Text] [Related]
18. PET in the diagnosis of neuroendocrine tumors. Sundin A; Eriksson B; Bergström M; Långström B; Oberg K; Orlefors H Ann N Y Acad Sci; 2004 Apr; 1014():246-57. PubMed ID: 15153441 [TBL] [Abstract][Full Text] [Related]
19. Validation studies on the 5-hydroxy-L-[beta-11C]-tryptophan/PET method for probing the decarboxylase step in serotonin synthesis. Lundquist P; Blomquist G; Hartvig P; Hagberg GE; Torstenson R; Hammarlund-Udenaes M; Långström B Synapse; 2006 Jun; 59(8):521-31. PubMed ID: 16565973 [TBL] [Abstract][Full Text] [Related]
20. Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP). Ambrosini V; Morigi JJ; Nanni C; Castellucci P; Fanti S Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):58-69. PubMed ID: 25677589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]